BBOT BRIDGEBIO ONCOLOGY THERAPEUTICS INC

BBOT to Participate in the Jefferies Global Healthcare Conference in London

BBOT to Participate in the Jefferies Global Healthcare Conference in London

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in a presentation at the Jefferies Global Healthcare Conference on Monday, November 17, at 2:30 p.m. GMT.  

A live webcast of the presentation will be accessible on the “” page of the BBOT website at . A replay of the webcast will be available for at least 90 days following the event.

About BBOT

BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit  and follow us on .

BBOT Contacts:

Investor Contact:

Heather Armstrong, Head of Investor Relations

BBOT



Media Contact:

Jake Robison

Inizio Evoke Comms



EN
03/11/2025

Underlying

BBOTBRIDGEBIO ONCOLOGY THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BRIDGEBIO ONCOLOGY THERAPEUTICS INC

 PRESS RELEASE
Free
BBOT BRIDGEBIO ONCOL...

BBOT to Participate in the Jefferies Global Healthcare Conference in L...

BBOT to Participate in the Jefferies Global Healthcare Conference in London SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in a presentation at the Jefferies Global Healthcare Conference on Monday, November 17, at 2:30 p.m. GMT.   A live webcast of the presentation will be accessible on the “” page of the BBOT website at . A replay of the webcast will be avail...

November 3, 2025 1 EN
Wedbush Research
  • Wedbush Research
XNCR XENCOR INC.
FATE FATE THERAPEUTICS INC
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
2303 UNITED MICROELECTRONICS CORP.
ROKU ROKU INC. CLASS A
TSEM TOWER SEMICONDUCTOR LTD
ARVN ARVINAS HOLDING
APRE APREA THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
ZNTL ZENTALIS PHARMACEUTICALS
RZLT REZOLUTE
IMNM IMMUNOME
TNGX TANGO THERAPEUTICS
GFS INC
TYRA GLOBALFOUNDRIES INC
NUVL TYRA BIOSCIENCES INC
BCAX NUVALENT INC
BBOT BICARA THERAPEUTICS INC.
BRIDGEBIO ONCOLOGY THERAPEUTICS INC
10/27/25 October 27, 2025 1 EN
David Nierengarten ... (+6)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
XNCR XENCOR INC.
ARVN ARVINAS HOLDING
APRE APREA THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
ZNTL ZENTALIS PHARMACEUTICALS
IMNM IMMUNOME
TNGX TANGO THERAPEUTICS
TYRA INC
NUVL TYRA BIOSCIENCES INC
BCAX NUVALENT INC
BBOT BICARA THERAPEUTICS INC.
BRIDGEBIO ONCOLOGY THERAPEUTICS INC
10/27/25 October 27, 2025 1 EN
 PRESS RELEASE
Free
BBOT BRIDGEBIO ONCOL...

Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Co...

Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglycemia Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT signaling in tumor cells without affecting glucose metabolismRobust monotherapy activity, as well as combination activity with BBOT’s KRASG12C ON/OFF inhibitor, BBO-8520, and panKRAS inhibitor, BBO-11818, was observed at well-tolerated dose l...

October 25, 2025 1 EN
 PRESS RELEASE
Free
BBOT BRIDGEBIO ONCOL...

BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as...

BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Data demonstrate potent suppression of MAPK signaling and viability in KRAS mutant cell lines, as well as anti-tumor activity across multiple KRASG12D and KRASG12V cell-derived xenograft (CDX) modelsBBO-11818’s selectivity for KRAS demonstrated by its >1000-fold lower potency against NRAS, HRAS, and BRAF-mutant cell linesEfficacy of the combination with BBOT’s RAS:PI3K⍺ breaker, BBO-10203, is driven...

October 23, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch